Insider Selling: Precigen (NASDAQ:PGEN) COO Sells $219,518.00 in Stock

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 33,772 shares of Precigen stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $6.50, for a total value of $219,518.00. Following the sale, the chief operating officer directly owned 497,751 shares of the company’s stock, valued at approximately $3,235,381.50. This represents a 6.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Precigen Stock Up 5.5%

Shares of PGEN stock opened at $6.89 on Thursday. Precigen, Inc. has a fifty-two week low of $1.70 and a fifty-two week high of $7.23. The firm has a market capitalization of $2.46 billion, a PE ratio of -6.62 and a beta of 1.02. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The stock’s 50-day simple moving average is $5.12 and its 200-day simple moving average is $4.46.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 484.64% and a negative net margin of 183.98%.The firm had revenue of $54.98 million for the quarter, compared to analyst estimates of $27.98 million. The company’s quarterly revenue was up 6322.7% on a year-over-year basis. Equities analysts expect that Precigen, Inc. will post -0.02 earnings per share for the current year.

Institutional Investors Weigh In On Precigen

Hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming purchased a new position in shares of Precigen during the 1st quarter valued at approximately $27,000. NBC Securities Inc. purchased a new stake in Precigen during the fourth quarter worth $38,000. Mason Investment Advisory Services Inc. acquired a new stake in Precigen during the fourth quarter valued at $42,000. Abel Hall LLC acquired a new stake in Precigen during the fourth quarter valued at $44,000. Finally, Royal Bank of Canada increased its holdings in Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,426 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 earnings beat: Precigen reported $54.98 million in revenue, far above the roughly $28 million analyst consensus, while earnings were $0.05 per share versus expectations for a loss of approximately $0.01–$0.02. Revenue increased sharply year over year, and the company posted $20.1 million in net income attributable to common shareholders. Precigen Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: PAPZIMEOS momentum is driving the business: PAPZIMEOS generated $53.1 million of Q2 net revenue, more than double the prior quarter. Patient-hub enrollment exceeded 500, and FDA-granted seven-year market exclusivity strengthens the product’s commercial outlook. Management said current resources and product revenue are expected to support cash-flow break-even by the end of 2026. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: HC Wainwright reiterated its Buy rating and $14 price target, well above recent trading levels. The firm’s endorsement reinforced the bullish reaction to the earnings report. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually heavy options activity suggests increased investor attention and potentially higher near-term volatility, but the report does not establish whether options traders are primarily bullish or bearish. Precigen Target of Unusually Large Options Trading
• Negative Sentiment: Insider selling is a counterpoint: Precigen executives, including the COO, CEO and CFO, have reported stock sales, with no insider purchases cited over the past six months. The latest COO sale was made under a pre-arranged Rule 10b5-1 plan, reducing its informational significance but still presenting a potential overhang. Precigen Insider Selling

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Citizens Jmp boosted their target price on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. HC Wainwright upped their price target on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $14.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.